NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/12/2025
Voltar para busca
Dado oficial do USPTO
VAPOURSOFT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
12/12/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
10
Data de depósito
14/12/2020
Data de registro
17/01/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/01/2023
Última transação
12/12/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
LAM,HAI-LY HUYNH
Unidade examinadora
N10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Consort Medical Limited
Representantes
Charles P. Guarino Moser Taboada
Classificação técnica
Classes Nice
Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 10
Hydrofluoroalkanes (HFA) powered and liquefied gas powered apparatus and instruments for use in or in relation to drug and pharmaceutical delivery deviceshydrofluoroalkanes (HFA) powered drug delivery systems in the nature of infusion and injection devices for administering drugs; hydrofluoralkanes (HFA) powered medical syringesmedical fluid auto-injectors for administering pharmaceuticals and drugs and apparatus and devices for the inhalation or injection of pharmaceuticals and drugsinjection needlesmedical fluid auto-injectors and syringes; hydrofluoralkanes (HFA) powered catheterstransfusion sets and injection syringes for administering drugs and pharmaceuticalsalso incorporating audiovisual and/or tactile patient feedback mechanisms relating to drug and pharmaceutical delivery dosagemeasuring and monitoring information; hydrofluoralkanes (HFA) powered medical syringesmedical fluid auto-injectorsdrug delivery systems comprised of implantable drug delivery ports incorporating audiovisual and/or tactile patient feedback mechanisms to convey dosagemeasuringmonitoring data for the purpose of facilitating and monitoring drug and pharmaceutical delivery and administration; medical syringes; medical syringe stoppers; hydrofluoroolefin (HFO) powered medical fluid auto-injectors and medical fluid injectors; hydrofluoroolefin (HFO) powered apparatus and devices for administering pharmaceuticals and drugsmedical apparatus in the nature of infusion and injection devices for administering drugsmedical tubing for administering drugshypodermic needles; hydrofluoroolefin (HFO) powered drug delivery apparatusdrug delivery systems comprised of drug delivery catheters and electromagnetic drug delivery apparatus for medical use; medical fluid auto-injectors; medical fluid injectors; disposable syringes and medical fluid injectors; hypodermic syringes; apparatus and devices for administering pharmaceuticals and drugsmedical apparatus in the nature of infusion and injection devices for administering drugsmedical tubing for administering drugshypodermic needles; sterile medical syringes and medical fluid auto-injectors for the administration of pharmaceuticals and drugs; cartridges sold empty and specially adapted for medical syringes; nozzles sold empty and specially adapted for medical syringes; drug delivery apparatusdrug delivery systems comprised of drug delivery catheters and electromagnetic drug delivery apparatus for medical use; oral and nasal medication dispensersaerosol dispensers for medical use; aerosol dispensers for medical purposes; structural replacement parts and fittings for all the aforesaid goods
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
RNWL
INTERNATIONAL REGISTRATION RENEWED
29/02/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
16/05/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
26/04/2023
FIMP
FINAL DISPOSITION PROCESSED
26/04/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/04/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
17/01/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
17/01/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
22/11/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/11/2022
PUBO
PUBLISHED FOR OPPOSITION
01/11/2022
GPNX
NOTIFICATION PROCESSED BY IB
31/10/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/10/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/10/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/10/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
23/09/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/09/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/09/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/09/2022
RFNT
REFUSAL PROCESSED BY IB
10/04/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/03/2022
GNRT
NON-FINAL ACTION E-MAILED
09/03/2022
CNRT
NON-FINAL ACTION WRITTEN
09/03/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/02/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/02/2022
ATRV
ATTORNEY REVIEW COMPLETED
08/02/2022
CREV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
12/01/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/12/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/12/2021
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
03/11/2021
RFNT
REFUSAL PROCESSED BY IB
18/07/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
21/06/2021
RFRR
REFUSAL PROCESSED BY MPU
21/06/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/06/2021
CNRT
NON-FINAL ACTION WRITTEN
11/06/2021
DOCK
ASSIGNED TO EXAMINER
07/06/2021
MAFR
APPLICATION FILING RECEIPT MAILED
23/01/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/01/2021
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
14/01/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VAPOURSOFT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.